rac-Des(4-cyclohexyl-L-proline) Fosinopril Acetic Acid

We are rac-Des(4-cyclohexyl-L-proline) Fosinopril Acetic Acid CAS:123599-78-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:rac-Des(4-cyclohexyl-L-proline) Fosinopril Acetic Acid
CAS.NO:123599-78-0
Synonyms:rac-Des(4-cyclohexyl-L-proline) Fosinopril Acetic Acid
[(2-Methyl-1-propionylpropoxy)(4-phenylbutyl)phosphinoyl]acetic acid
4-cyclohexyl-1-(((R)-((1S)-2-methyl-1-(1-oxopropoxy) propoxy) (4-phenylbutyl) phosphinyl) acetyl)
Propanoic acid, 1-[[(carboxymethyl)(4-phenylbutyl)phosphinyl]oxy]-2-methylpropyl ester
 
Physical and Chemical Properties:
Density 1.2±0.1 g/cm3
Boiling Point 519.8±60.0 °C at 760 mmHg
Molecular Formula C19H29O6P
Molecular Weight 384.404
Flash Point 268.2±32.9 °C
 
Specification:
Appearance:White to off-white crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Fosinopril sodium(CAS:88889-14-9).

rac-Des(4-cyclohexyl-L-proline) Fosinopril Acetic Acid


Related News: The continuous acceleration of the industrial transfer process has provided a huge market space for the fine chemical intermediate industry.6-fluoro-5-methylpyridin-3-amine CAS:186593-48-6 Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: “Within the top 20 global companies that spent the most on R&D in 2018, the top spender – despite having the second smallest annual revenue of the group at $15.28 billion – is Celgene, whose R&D spend was equal to 37% of its annual revenue.2,6-dicloro-5-fluoropiridin-3-amina CAS:152840-65-8 At present, China’s bulk drug industry is mainly focused on bulk drug substances, and there is huge room for development in terms of specialty drug substances and patented drug substances.2-(Chloromethyl)-3,4-dimethoxypyridine Hydrochloride At present, China’s bulk drug industry is mainly focused on bulk drug substances, and there is huge room for development in terms of specialty drug substances and patented drug substances.At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth.

Related Products
Product Name
4-nitro-m-cresol View Details
2,4,6-tris(3-bromophenyl)-1,3,5-triazine View Details
2-Fluoro-4-methoxybenzoic acid View Details
4-Bromobutyryl chloride manufacturer 2-Acetyl-3,5-dimethylpyrazine manufacturer 2-Bromotriphenylene manufacturer cyclohexylamine manufacturer 1-Methylazepan-4-one manufacturer